Free Trial
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

Astellas Pharma logo
$9.60 -0.05 (-0.52%)
As of 07/3/2025 12:53 PM Eastern

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Key Stats

Today's Range
$9.59
$9.98
50-Day Range
$9.12
$10.15
52-Week Range
$8.37
$13.14
Volume
41,054 shs
Average Volume
133,851 shs
Market Capitalization
N/A
P/E Ratio
56.47
Dividend Yield
3.65%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALPMY Stock News Headlines

Post-Halving = Profit Season (Here’s How to Win It)
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
See More Headlines

ALPMY Stock Analysis - Frequently Asked Questions

Astellas Pharma's stock was trading at $9.66 at the beginning of 2025. Since then, ALPMY shares have decreased by 0.6% and is now trading at $9.60.

Astellas Pharma Inc. (OTCMKTS:ALPMY) issued its quarterly earnings data on Friday, April, 25th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.15 by $0.12. The business earned $3.22 billion during the quarter, compared to analyst estimates of $3.02 billion. Astellas Pharma had a trailing twelve-month return on equity of 16.55% and a net margin of 2.65%.

Astellas Pharma shares split on Wednesday, April 2nd 2014.The 5-4 split was announced on Friday, March 14th 2014. The newly issued shares were issued to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

Astellas Pharma subsidiaries include Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and others.

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/25/2025
Today
7/04/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
Fax
N/A
Employees
14,754
Year Founded
1923

Profitability

Trailing P/E Ratio
56.47
Forward P/E Ratio
22.86
P/E Growth
N/A
Net Income
$334.93 million
Pretax Margin
1.63%

Debt

Sales & Book Value

Annual Sales
$12.56 billion
Cash Flow
$1.79 per share
Price / Cash Flow
5.36
Book Value
$5.52 per share
Price / Book
1.74

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.23

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (OTCMKTS:ALPMY) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners